Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry

Kardiologia Polska

Volumn 72, Issue 12, 2014, Pages 1394-1399

  Rzeszutko, Łukasz ^a   Siudak, Zbigniew ^b   Włodarczak, Adrian ^c   Lekston, Andrzej ^d   Depukat, Rafał ^a   Ochała, Andrzej ^d   Gil, Robert J ^e,f   Balak, Wojciech ^g   Marć, Miłosz ^h   Kochman, Janusz ⁱ   Zasada, Wojciech ^j   Dudek, Dariusz ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Miedziowe Centrum Zdrowia SA   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Central Clinical Hospital   (Poland)

^f POLISH ACADEMY OF SCIENCES   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h Department of Cardiology Municipial Hospital   (Poland)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j Krakow Cardiovascular Research Institute   (Poland)

more..

Author keywords

Acute coronary syndrome; Bioresorbable; Registry; Stable angina; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BIORESORBABLE VASCULAR SCAFFOLD; CORONARY STENTING; DISEASE REGISTRY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; SAPHENOUS VEIN GRAFT; STABLE ANGINA PECTORIS; TISSUE SCAFFOLD; UNSTABLE ANGINA PECTORIS; AGED; ANGINA, STABLE; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; POLAND; REGISTER; RETROSPECTIVE STUDY;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLAND; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84922755482     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.a2014.0147     Document Type: Article

References (15)

1. Mahdi NA, Lopez J, Leon M et al. Comparison of primary coronary stenting to primary balloon angioplasty with stent bailout for the treatment of patients with acute myocardial infarction. Am J Cardiol, 1998; 81: 957-963.
2. Kolh P, Wijns W, Danchin N et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Guidelines on myocardial revascularization. Eur Heart J, 2010; 31: 2501-2555.
3. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012; 33: 2569-2619.
4. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 2007; 370: 937-948.
5. Stone GW, Lansky A, Pocock SJ et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction N Engl J Med, 2009; 360: 1946-1959.
6. Kandzari DE, Leon MB, Meredith I et al. Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program: Comparison of Safety and Efficacy With First-Generation Drug-Eluting and Bare-Metal Stents. J Am Coll Cardiol Cardiovasc Interv, 2013; 6: 504-512.
7. Dziewierz A, Siudak Z, Rakowski T et al. Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol, 2011; 100: 139-145.
8. Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation, 2009; 119: 3198-3206.
9. Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol, 2012; 60: 1340-1348.
10. Hofma SH; van der Giessen WJ; van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 2006; 27: 166-170.
11. Brugaletta S, Radu MD, Garcia-Garcia HM et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 2012; 221: 106-112.
12. Sarno G, Bruining N, Onuma Y et al. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging, 2012; 28: 51-58.
13. Depukat R, Rzeszutko L, Dudek D. Regeneration of vessel wall functionality and vascular restoration therapy with biodegradable stents: current status. Curr Pharm Biotechnol, 2012; 13: 2440-2448.
14. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet, 2009; 14: 897-910.
15. Gori T, Schulz E, Hink U et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention, 2013 Sep 4, doi: pii: 20130825-02 [Epub ahead of print].